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ABSTRACT 
Background. Few studies have investigated the prognostic factors for nasal natural killer 
(NK)/T-cell lymphoma.  
Methods. A retrospective study.  
Results. High serum levels of C-reactive protein (≥1.0 mg/dl), lactate dehydrogenase 
(≥350 IU/l), and soluble interleukin-2 receptor (≥600 U/ml) were associated with worse 
prognosis. A prognostic score was devised by totaling the number of these three 
predictors: 0 or 1 = score 0; and 2 or 3 = score 1. As for tumor invasion, local invasion 
beyond the nasal cavity was associated with poor prognosis, and a prognostic score was 
devised as: tumor restricted to nasal cavity, yes = score 0; no = score 1. A novel prognostic 
index was established based on these scores, from 0 to 2. Disease-specific survival rates 
at five years were: 90.0% for NPI=0; 29.3% for NPI=1; and 0.0% for NPI=2.  
Conclusion. Our NPI is valid for anticipating prognosis of nasal NK/T-cell lymphoma.  
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INTRODUCTION 
The subsets of extranodal natural killer (NK)/T-cell lymphoma, nasal type, are classified 
as nasal or extranasal NK/T-cell lymphoma. Nasal NK/T-cell lymphoma covers the 
subclassification of upper aerodigestive tract NK/T-cell lymphomas including nasal 
cavity, nasopharynx, oral cavity, oropharynx, and hypopharynx, while non-upper 
aerodigestive tract NK/T-cell lymphomas include skin, gastrointestinal tract, bone 
marrow, lung, extremities, orbit, adrenal gland, testis and central nervous system 1. 
Although the definition of the primary region of nasal NK/T-cell lymphoma indicates a 
very limited area (nasal cavity, nasopharynx), about 80% of extranodal NK/T-cell 
lymphoma, nasal type, represent nasal NK/T-cell lymphoma 2.  
The majority of cases with nasal NK/T-cell lymphoma might be first diagnosed 
in an otolaryngology and head and neck surgery department. Due to the rarity of this 
disease, nasal polyps or nasal carcinoma will usually be suspected at the first presentation, 
and the diagnosis mainly depends on pathological studies including 
immunohistochemical staining. Correct diagnosis may thus be delayed, and after 
establishment of the diagnosis, almost all patients are referred to hematologists or 
oncologists for treatment. The patient will then be re-classified to determine a therapeutic 
strategy. This represents a time-consuming process from first presentation to the start of 
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treatment. Otolaryngologists and head and neck surgeons seldom take part in the 
treatment of this disease, but are the most familiar with the anatomy and imaging studies 
of this region. A good, original prognostic index for nasal NK/T-cell lymphoma for use 
mainly by otolaryngologists and head and neck surgeons would be valid for promptly 
anticipating prognosis and facilitating timely decision-making on treatments for this 
disease. 
Prognostic factors in extranodal NK/T-cell lymphoma, nasal type, have yet to be 
fully defined. Ann Arbor staging for lymphomas and the international prognostic index 
(IPI) 3 have generally been applied to predict prognosis for this type of lymphoma. 
However, these methods are not necessarily suitable, particularly for nasal NK/T-cell 
lymphoma. Ann Arbor staging was originally developed for Hodgkin lymphoma 4, and 
according to this classification system, most cases of nasal NK/T-cell lymphoma are 
categorized as stage I or II 5 regardless of their poor prognosis. Tumors in the nasal ± 
paranasal/nasopharynx regions are simply counted as occupying one site, irrespective of 
whether the tumor is bulky or not. Some authors have reported that Ann Arbor staging 
system did not predict the prognosis of extranodal NK/T-cell lymphoma 6. IPI, which was 
developed for aggressive non-Hodgkin lymphoma, includes age, serum lactate 
dehydrogenase (LDH) level, extranodal sites, and performance status (PS) 3. This index 
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does not consider local tumor invasiveness as a prognostic factor. Similar to the situation 
with the Ann Arbor staging system, the majority of nasal NK/T-cell lymphomas show low 
IPI scores 5, 6. However, despite the classification as early stage according to these systems, 
overall outcomes for this disease are poor 7. Due to the unbalanced distribution of patients 
within these systems and their inability to identify patients with more aggressive disease 
among the low-risk category, more suitable classifications are needed to more accurately 
predict the prognosis of nasal NK/T-cell lymphoma. Kim et al. 6 reported local tumor 
invasiveness as the most important prognostic factor predicting poor prognosis of early 
stage nasal NK/T-cell lymphoma. Robbins et al. 8, as head and neck surgeons, staged nasal 
lymphoma using the American Joint Committee TNM system for nasal carcinoma. 
Although NK/T-cell lymphoma had been excluded from their study, this method made it 
easy to understand the progress of nasal lymphomas.  
The present study analyzed several prognostic factors, including blood 
examinations and local invasion of the tumor. The aim of the study was to develop a novel 
prognostic index (NPI) specifically for nasal NK/T-cell lymphoma, in cooperation with 
pathologists, hematologists, oncologists, and epidemiologists, to be utilized for 
outpatients presenting to otolaryngology and head and neck surgery departments. 
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SUBJECTS AND METHODS 
Patients   
The clinical records of 36 patients with nasal NK/T-cell lymphoma who had been 
first treated between 1996 and 2011 were collected from 12 hospitals. The study protocols 
were approved by the institutional review board at Okayama University. 
For the diagnosis of NK/T-cell lymphoma, histopathological examination was 
conducted on paraffin sections of formalin-fixed tissue after staining with hematoxylin 
and eosin. Immunohistochemical staining for cCD3+, CD5-, TIA-1+, granzyme B+ and 
CD56+, and positive in situ hybridization for Epstein-Barr virus (EBV)-encoded RNA 
were required to confirm the diagnosis 9. All cases were diagnosed in the Department of 
Pathology at Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences. The anatomical boundaries of extranodal NK/T-cell lymphoma 
remain still ambiguous. In the present study, according to a recent review article 1, nasal 
NK/T-cell lymphoma was defined as a primary tumor involving the nasal cavity (± 
nasopharynx), regardless of dissemination to other sites. 
Information about each patient was collected from a questionnaire containing the 
following items: age and sex; dates of first presentation and last follow-up; results of 
blood examination at diagnosis; PS; tumor invasiveness (extracted from findings or 
images of computed tomography (CT) ± 18F-deoxyglucose positron emission 
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tomography); methods of treatment; and outcome and cause of death.  
Treatment and Follow-up 
All patients received chemotherapy, and 29 of the 36 cases (81%) also received 
radiotherapy. The choice of regimen was at the discretion of the attending physician. 
Chemotherapeutic regimens included DeVIC (carboplatin, etoposide (ETP), ifosfamide 
(IFM), dexamethasone (DMS)) (n=13, 36%), CHOP (cyclophosphamide, doxorubicin, 
vincristine, prednisone) (n=13, 36%), SMILE (DMS, methotrexate, IFM, L-asparaginase, 
ETP) (n=5, 14%), and others (n=9, 25%). Some patients received more than one of the 
above-mentioned regimens. Since this was a retrospective multicenter clinical study with 
inconsistent treatment methods at different institutions, we did not aim to analyze 
relationships between survival time and detailed treatment regimens. Patients were 
followed until death or last medical examination.  
Statistical Analysis 
Categorical variables are presented as numbers and percentages, and continuous 
variables are presented as mean ± standard deviation (SD). The significance of baseline 
differences was determined using the 2 test or the unpaired t-test, as appropriate. Survival 
was estimated using the Kaplan-Meier method, and differences in survival between 
groups were assessed by log-rank test. Survival times were defined as the period of time 
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to death from the establishment of the diagnosis. Subjects were treated as censored when 
cases were lost to follow-up or the patient chose to withdraw from the study during the 
observation period. Cox proportional-hazards models for both uni- and multivariate 
analyses were used to determine the contribution of each variable. When conducting 
multivariate analysis, imputation was performed using median values of each variable. 
Since this study included only a small number of cases, analysis of many of the prognostic 
factors by multivariate analyses in the same model might have been problematic. To 
develop a NPI exclusive to nasal NK/T-cell lymphoma, we assumed two theoretically 
independent domains related to poor prognosis: results of blood examination; and 
expansion of the local tumor. For blood examinations, Pearson’s correlation coefficients 
were calculated for potential factors that were significantly associated by survival 
analysis or univariate analysis before simply summing up a uni-dimensional score. We 
then dichotomized this score according to the distribution (dichotomous score for blood 
examination). Next, we considered the score for tumor invasiveness. We tried to compare 
the various kinds of classification for expansion of the tumor, because no standard 
classifications have been determined. Then, from both clinical importance and magnitude 
of effect with poor prognosis, we decided on one boundary for assessing tumor 
invasiveness (dichotomous score for tumor invasion). Lastly, we conducted multivariate 
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analysis using Cox’s proportional hazard model to confirm that these two domains were 
actually associated with prognosis even after mutually adjustment and constructed NPI 
from these two tentative dichotomous scores. 
A value of P<0.05 (two-sided) was considered statistically significant. All 
analyses were performed using SPSS version 20.0J software (SPSS, IBM Corp, Armonk, 
New York, USA).  
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RESULTS 
Patient Characteristics and Outcomes 
 The sample for this study consisted of 36 patients with primary nasal NK/T-cell 
lymphoma. Baseline characteristics are shown in Table 1; data on some variables were 
missing for some patients. Of the 36 patients with nasal NK/T-cell lymphoma, 19 (53%) 
survived and 17 (47%) had died of the disease by the final observation. Mean age at initial 
presentation was 55 years (range, 21-79 years). Patients comprised 22 men (61%) and 14 
women (39%). As for local tumor invasion, 15 cases (42%) were restricted to the nasal 
cavity. The exact distribution of Ann Arbor staging was: I, n=22; II, n=10; III, n=1; and 
IV, n=3. The distribution for IPI score was: 0, n=5; 1, n=18; 2, n=6; 3, n=4; and 4, n=2 
(missing, n=1). Significant crude associations were identified for C-reactive protein 
(CRP), lactate dehydrogenase (LDH), and soluble interleukin-2 receptor (sIL-2R). CRP 
levels were determined in 34 patients, and the median value was 0.47 mg/dl (range, 0.0-
22.0 mg/dl; reference range, <0.30 mg/dl). Serum levels of LDH were available for 35 
patients, with a median value of 244 IU/l (range, 112-1418 IU/l; reference range, 120-240 
IU/l). Similarly, the median sIL-2R level for 31 patients was 541 U/ml (range, 122-6976 
U/ml; reference range, 145-519 U/ml).  
Survival Analysis of Prognostic Factors 
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Mean survival after initial diagnosis of nasal NK/T-cell lymphoma was 39 
months (range, 4-147 months). The disease-specific five-year survival rate from initial 
diagnosis was 43.7% (Fig. 1). 
Results of survival analysis are shown in Table 2. High serum levels of CRP, 
LDH, and sIL-2R represented factors significantly associated with poor prognosis. Local 
invasiveness of tumor beyond the nasal cavity (n=21, 58%) was also associated with poor 
prognosis. Ann Arbor staging was not associated with prognosis, even employing two 
different cut-off points. IPI ≥2 (n=12) was not associated with poor prognosis. While IPI 
≥3 (n=6) was significantly associated with poor prognosis, the number of cases was small 
compared to the actual number of deaths (n=17). 
Pearson’s correlation coefficients among CRP, LDH, and sIL-2R were all 
significant (range, 0.483-0.542). We then summed up values to create a uni-dimensional 
score (range, 0-3) based on the presence/absence of these three unfavorable factors. Cox’s 
proportional hazards analysis revealed this score as a significant factor predicting disease-
specific death from nasal NK/T-cell lymphoma (Table 3a). We dichotomized the scores 
for NPI (0 or 1 = NPI 0 and 2 or 3 = NPI 1) and the dichotomous score for blood 
examination was also significantly associated with poor prognosis (hazard ratio (HR), 
4.873; 95% confidence interval (CI), 1.813-13.096).  
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We tried to compare the various kinds of classification (restricted to nasal cavity 
and ethmoidal sinus vs. beyond; restricted to nasal cavity and maxillary sinus vs. beyond; 
and restricted to nasal cavity and paranasal sinuses vs. beyond) for local expansion of the 
tumor, and considered local invasiveness of the tumor restricted to the nasal cavity as the 
most predictable factor (HR, 3.575; 95%CI, 1.155-11.072), regardless of dissemination 
to other sites (within nasal cavity=0, beyond=1) (Table 3b). 
Multivariate analysis using the Cox’s proportional hazard model identified the 
dichotomous score of blood examination and the dichotomous score of local tumor 
invasion as independent factors for predicting death from nasal NK/T-cell lymphoma, 
even after mutually adjustment (Table 4). 
Disease-specific survival rates at five years for the three groups were 90.0% for 
NPI=0 (low risk, n=12), 29.3% for NPI=1 (intermediate risk, n=16), and 0.0% for NPI=2 
(high risk, n=8) (P<0.0001) (Fig. 2). 
 
14 
 
DISCUSSION 
Our findings demonstrated that the prognosis of patients with nasal NK/T-cell 
lymphoma was well predicted by local invasion of the primary tumor and three values 
(CRP, LDH, and sIL-2R) from blood examination. This NPI needs only CT imaging of 
primary tumors and the results of blood examination in addition to accurate pathological 
diagnosis, and so will be valid for promptly anticipating prognosis and aiding timely 
decisions on treatment policy for this disease. Since the disease-specific survival rate at 
five years for the group classified as low-risk (NPI=0) by NPI were excellent (90.0%), 
those classified in the low-risk group by NPI could potentially benefit from less-
aggressive therapy, such as surgery or field radiotherapy without chemotherapy. 
With upper aerodigestive tract NK/T-cell lymphoma, survival outcomes of nasal 
and extra-nasal NK/T-cell lymphomas were comparable 1. Including non-upper 
aerodigestive tract NK/T-cell lymphoma, disease type nasal came to represent a factor 
associated with significantly better prognosis 2, 10. The largest retrospective study of NK 
cell leukemia and extranodal NK/T-cell lymphoma in Japan 2, which included 123 cases 
of nasal NK/T-cell lymphoma (total 172 cases), revealed tumor type (nasal or non-nasal), 
clinical stage, PS, and number of extranodal involvements as significant prognostic 
factors. The largest Korean study 11 of 262 cases of NK/T-cell lymphoma, nasal type, 
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identified an excellent index including B symptoms, clinical stage, serum LDH level and 
regional lymph node involvement. However, these classification and indices were not 
exclusive for nasal NK/T-cell lymphoma. Some studies have identified the IPI category 
as prognostic for extranodal NK/T-cell lymphoma 2, 5, 6, and in the present study, IPI ≥ 3 
was indeed associated with worse prognostic factor on univariate analysis, although an 
unbalanced distribution of patients within this system was observed. Actually, IPI has 
been reported to perform less well in low-score groups 12.  
Paranasal extension of nasal lymphomas has been identified as a significant 
predictor of survival in several studies 8, 13, 14, and we also investigated tumor invasion 
beyond the nasal cavity as an indication of advanced disease state for nasal NK/T-cell 
lymphoma. We tried many types of analysis for tumor invasiveness, and finally found that 
tumor invasion beyond the nasal cavity as the most valuable factor, significantly 
associated with worse disease-specific survival regardless of tumor dissemination to sites 
other than the primary lesion. UICC staging for nasal carcinoma seemed to be difficult to 
be determined by doctors other than otolaryngologists or head and neck surgeons, because 
the definition of subsite in the nasal cavity is too complicated. On the other hand, whether 
the primary tumor is restricted to the nasal cavity can be relatively easily determined by 
any doctor on CT imaging.  
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Both activated T cells and lymphoma cells produce sIL-2R, and serum levels of 
sIL-2R reflect the prognosis in patients with peripheral T-cell lymphoma as well as diffuse 
large B-cell lymphoma 15. To the best of our knowledge, the present study might be the 
first report serum levels of sIL-2R as one of the prognostic factors for NK/T-cell 
lymphoma. Among the three values included in the score of blood examination (sIL-2R, 
CRP, and LDH), each of which showed significant prognostic value on univariate analysis, 
sIL-2R was the strongest prognostic factor. CRP is known as a prognostic marker in 
several malignancies, including both Hodgkin’s lymphoma 16 and non-Hodgkin’s 
lymphoma 17. The present study revealed this as one of the prognostic factors for nasal 
NK/T-cell lymphoma. Although we lacked the data about B-symptoms, serum levels of 
CRP were said to be associated with B-symptoms 17. Serum LDH levels are reportedly 
associated with survival outcomes for extranodal NK/T-cell lymphoma 18, similar to our 
findings. Although we did not adopt high IPI score (≥3) for our NPI due to the unbalanced 
distribution of patients with nasal NK/T-cell lymphoma to each category of the IPI, serum 
LDH level was associated with IPI score, stage, and lymph node invasiveness 18. Our 
index of blood examination with the combination of these three kinds of markers thus 
might well indicate the status of patients with nasal NK/T-cell lymphoma. 
According to a large Korean study 11 of NK/T-cell lymphoma, nasal type, 
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invasion of regional lymph nodes may offer a more powerful predictive factor of poor 
survival than local tumor invasiveness. In the present study, involvement of the cervical 
lymph nodes was not a worse prognostic factor for nasal NK/T-cell lymphoma. In a large 
retrospective study of 128 extranodal NK/T-cell lymphomas 19, absolute lymphocyte 
count (ALC) prior to treatment was identified as a powerful prognostic factor in 
extranodal NK/T-cell lymphoma. In our series, none of the patients with nasal NK/T-cell 
lymphoma showed low ALC. These discrepancies between other studies and the present 
might be a result of our limitation in focusing solely on nasal NK/T-cell lymphoma. A 
prospective study that included 29 cases of nasal NK/T-cell lymphoma 20 revealed EBV-
DNA level in plasma and mono-nuclear cells from peripheral blood as a good indicator 
for response and overall survival of nasal NK/T-cell lymphoma. Although this subject 
was not analyzed in the present study, a key advantage of this NPI might be its simplicity. 
The present study involved several limitations. First, the rarity of this disease 
limits large-scale randomized studies, and since this is a multicentric retrospective study 
some patients had incomplete dataset and the treatments were variable. However, we 
focused on the prognostic factors of this disease, and our findings have important 
implications on anticipating prognosis of this disease. Second, there was a possibility that 
many of the cases in the present study were in a relatively early stage of the disease, due 
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to the fact that almost all cases in this study had first presented to the Department of 
Otolaryngology and head and neck surgery, probably without serious conditions. 
However, despite the bias of the patient selection method, characteristics of patients in 
this series were similar to other previous reported Asian studies 2, 5, 11. The disease-specific 
survival rate from diagnoses of nasal NK/T-cell lymphoma in the present study (43.7% at 
five years) was also comparable with other Asian studies 5, 7. To confirm the efficacy of 
the NPI, application of the NPI to some validation cohort at another institutions with no 
relationship to our groups will be necessary, although this might be difficult due to the 
paucity of patients with nasal NK/T-cell lymphoma. Third, since we could not control any 
other potential confounders (e.g., age, sex) due to the small sample size, residual 
confounding might remain. However, it is unlikely that such bias could explain all the 
present results. Furthermore, age is usually a strong predictive variable in most diseases, 
and can be taken into account when selecting treatments separately to NPI. Lastly, 
misclassification of exposure variables (for blood examination and for tumor invasion) 
was considered non-differential and might affect effect estimates to toward the null. The 
significant results thus did not change substantially. 
CONCLUSION 
In conclusion, this NPI based on simple clinical parameters may be useful to 
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stratify patients into different risk groups. Survival of patients with nasal NK/T-cell 
lymphoma could be improved by prompt anticipation of patient prognosis using this NPI. 
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FIGURE LEGENDS 
 
Figure 1. The disease-specific survival rate for the 36 patients with nasal NK/T cell 
lymphoma was 43.7% at 5 years. 
 
Figure 2. We devised a new prognostic index (NPI) for nasal NK/T cell lymphoma based 
on the presence of 2 unfavorable characteristics potentially present in patients: local 
tumor invasion; and blood examination. Scores were assigned from 0 to 2. The disease-
specific survival rate at 5 years for the 3 groups were: 90.0% for NPI=0 (n=12); 29.3% 
for NPI=1 (n=16); and 0.0% for NPI=2 (n=8) (P<0.0001) 
